Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (351)	2/22/2003 6:43:10 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 469

I have no answers, and I'm getting ticked with reg Fd. Nobody answers questions for anyone. There's tons of information out there for the large companies, as underwriters have "snooping" budgets. But small caps are free to just shine us small fry on. The way it reads...... Kirin loses if their antibody isn't best, but they don't lose completely as they will still have asia/australasia. They probably get asia/australasia on better terms than they would otherwise, and this way they're relatively certain to get it. HGSI wins, period. If the CAT antibody is not best, HGSI retains the remainder of world. Sound reasonable? Now..... the CAT agreement presumably had a non-compete clause. I suspect that means that CAT would get royalties on the sale of a Kirin product, or that the CAT antibody will be returned, kostenloss, if HGSI selects the Kirin MAb. Sound reasonable again, or for the first time? :-) That yet another question that CAT management should clarify??